On September 11, 2020 Targazyme Inc., a late clinical-stage biopharmaceutical company developing novel fucosyltransferase enzyme technologies and products to improve clinical efficacy, safety, and cost of care outcomes for immuno-oncology and stem cell transplantation, reported that it has recruited cancer immunotherapy industry veteran James Caggiano to be the CEO, focused initially on its oncology business (Press release, Targazyme, SEP 11, 2020, View Source [SID1234565036]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A former US Army Officer, Jim Caggiano brings nearly 30 years of immuno-oncology, pharmaceutical, and medical device experience at successful companies such as TAP Pharmaceuticals, Allergan, Abbott Laboratories, Valeant, and Dendreon. As President at Valeant, Caggiano led the successful business turnaround of Dendreon, doubled the value of Dendreon by selling it to Sanpower Group for $820M, and became its CEO. Under his leadership, Dendreon earned over $100M in EBIT in 2018 and 2019.

"We welcome Jim Caggiano to our Targazyme team and look forward to his leadership with advancing our oncology assets to making a life-changing difference for cancer patients and their families worldwide," said Lynnet Koh, Targazyme’s Founder and Executive Chairman of Targazyme. "Caggiano brings a track record of delivering major shareholder value through successful execution of sell-side deal transactions and driving major commercial revenue growth. His military leadership skills positions the company for consistently delivering on key milestones on time and on budget."

"I’m honored to join Targazyme at this exciting and pivotal time in its history," said Caggiano. "I look forward to working with the team here to capitalize on the impressive results of the past and to move these very promising, life-saving therapies forward, ultimately enhancing the lives of cancer patients."

On September 11, 2020 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, reported that CEO, John Climaco, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on Wednesday, September 16th, 2020 at 9:30 AM EDT (Press release, CNS Pharmaceuticals, SEP 11, 2020, View Source;co-22nd-annual-global-investment-conference-301128132.html [SID1234565035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference:

Date:

Wenesday, September 16th, 2020

Time:

9:30 AM EDT

Link:

View Source

A replay of the presentation will be available on the Company’s website for 90 days following the event. Members of management will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with Company management should contact their H.C Wainwright representatives.

On September 11, 2020 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 11:00 AM EDT (Press release, Regulus, SEP 11, 2020, https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-hc-wainwright-22nd-annual-virtual-global-investment-conference-301128135.html [SID1234565034]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the investor relations section of the Company’s website at www.regulusrx.com.

On September 11, 2020 Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, reported that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a final local coverage article (LCA) to provide Medicare benefits for serial use of the Signatera molecular residual disease (MRD) test in patients with a history of colorectal cancer (Press release, Natera, SEP 11, 2020, View Source [SID1234565033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Noridian article is in line with the positive coverage determination issued by the CMS Molecular Diagnostics (MOLDX) program last week via Palmetto GBA and shares the same effective date of October 18th, 2020.

On September 11, 2020 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, AIkido Pharma, SEP 11, 2020, https://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301128171.html [SID1234565032]). The conference is being held on September 14-16, 2020 virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will provide an overview of the Company’s business during the live presentation.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference.

Event: H.C. Wainwright 22nd Annual Global Investment Conference (Virtual Conference)
Date: Tuesday, September 15, 2020
Time: 3:00 p.m. (Eastern Time)
Location: Virtual Conference
Webcast: View Source

The presentation will be webcast live. To access the webcast, please visit www.hcwevents.com . The webcast replay will remain available for 90 days following the live presentation.

About H.C. Wainwright

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.